CTL019 and product out-licensing to drive 2017
We expect Oxford BioMedica’s (OXB’s) strategic vision to come to further fruition through 2017/18 with both the potential approval of Novartis’s...
136 Views
Encouraging CTL019 data in paediatric r/r B-ALL
At ASH this weekend, Novartis presented data from its global registration trial (ELIANA) of CTL019 in relapsed/refractory (r/r) paediatric and...
91 Views
Orchard deal adds to growing revenue stream
Oxford BioMedica’s (OXB’s) recently announced strategic alliance with Orchard Therapeutics further underpins the value the wider cell therapy...
93 Views